FDA approval of Akynzeo®

The U.S. Food & Drug Administration approves Helsinn's drug 'Akynzeo' for the prevention of acute and delayed phase nausea and vomiting in patients undergoing cancer chemotherapy.

CHMP Positive Opinion for Akynzeo® in the European Union

European Medicines Agency (EMA) has adopted a positive opinion recommending that Akynzeo®(netupitant-palonosetron),  be granted approval for the prevention of acute and delayed nausea and vomiting in patients undergoing highly emetogenic cisplatin‑based and moderately emetogenic cancer chemotherapy.

 

News
Prev Next
News

June 25, 2015

Helsinn is delighted to be able to support this event at the leading congress for supportive ...

News

June 02, 2015

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27t...

News

June 01, 2015

Helsinn, the Swiss Group focused on building quality cancer care, announces today that its re...

News

May 27, 2015

The European approval of ALOXI® for paediatric use follows the FDA approval in May 2014 of AL...